Status:
COMPLETED
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
Lead Sponsor:
University College, London
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and bexarotene, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giv...
Detailed Description
OBJECTIVES: Primary * Confirm the feasibility and efficacy of the combination of gemcitabine hydrochloride and bexarotene in patients with cutaneous T-cell lymphoma whose disease is no longer contro...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed cutaneous T-cell lymphoma (CTCL) including its variants (e.g., mycosis fungoides and Sézary syndrome)
- CTCL stage IB, IIA, IIB, III or IVA disease
- No visceral involvement (i.e., stage IVB disease)
- Lymphadenopathy is allowed
- Patients must have developed progressive disease after receiving or have been refractory to at least 1 course of prior standard, systemic, skin-directed therapy (e.g., interferon, chemotherapy, or denileukin diftitox \[Ontak®\])
- No CD30 + (Ki1+ve) anaplastic large cell lymphoma
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy \> 6 months
- Hemoglobin ≥ 9.0 g/dL (transfusions and/or erythropoietin are allowed)
- ANC \> 1.5 x 10\^9/L
- Platelet count ≥ 100 x 10\^9/L
- Total bilirubin ≤ 1.25 times upper limit of normal (ULN)
- AST and ALT ≤ 2 times ULN
- Serum creatinine ≤ 2 times ULN
- No clinically significant active infection
- No uncontrolled diabetes mellitus
- No excessive alcohol consumption
- No biliary tract disease
- No history of pancreatitis
- HIV negative
- Hepatitis B and C negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 month after study participation
- No other malignancy within the past 5 years except curatively treated basal or squamous cell skin cancer, cervical epithelial neoplasm CIN1, or carcinoma in situ
- No other significant medical or psychiatric condition that would preclude study compliance
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since any prior investigational agent
- More than 2 weeks since prior topical steroids or more than 4 weeks since prior systemic steroids
- Local radiotherapy may be given to isolated symptomatic tumour nodules that require immediate treatment for up to 2 weeks prior to study drugs
- No prior treatment with bexarotene (Targretin®)
- No concurrent anticancer therapy
- No concurrent investigational agent
- No concurrent drug therapy with other medications that can elevate triglycerides or cause pancreatic toxicity (e.g., gemfibrozil)
- No concurrent warfarin
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00660231
Start Date
March 1 2008
End Date
January 1 2014
Last Update
December 3 2014
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom, LS9 7TF
2
Saint Bartholomew's Hospital
London, England, United Kingdom, EC1A 7BE
3
St. Thomas' Hospital
London, England, United Kingdom, SE1 7EH
4
Christie Hospital
Manchester, England, United Kingdom, M20 4BX